Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Biogen Inc.

35 indications, side-by-side phase, drug & LoA

$194.24

-4.86 (-2.44%)

A 92Pipeline Score Undervalued Biotech · Commercial
Market Cap
28.61 B
EPS
9.35
P/E Ratio
20.79 $
Value Trade
173.56 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    2.48 B

  • R&D Expenses

    539.00 M

  • Operating CF

    645.50 M

  • Total Assets

    29.48 B

  • Total Liabilities

    10.83 B

  • Equity

    18.65 B

  • D/E Ratio

    12,345

1.01 %
Week
2.35 %
1 Month
1.56 %
3 Month
14.96 %
6 Month
-32.16 %
5 Year
6,722.46 %
All Time
Cash Data
Profitable

  • Cash Position

    3.41 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    Apr 29, 2026
Overview
Volume
1.07 M
52 Week Range
121.05 - 205.97
% held by Insiders
0.88 %
% held by Institutions
93.7 %
Enterprise Value
30.89 B
Total Shares
147.68 M
Short %
3.24 %
Float Shares
147.39 M
Company Description
HQ: 225 BINNEY STREET, CAMBRIDGE, ...
Employees:7,500
https://www.biogen.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout example
felzartamab Antibody-mediated rejection (AMR) in kidney transplant recipients
Phase 2
—
Antibody-Drug Conjugates (ADCs)
Immunology
felzartamab Antibody-mediated rejection (AMR) in kidney transplant recipients
Phase 2
—
Antibody-Drug Conjugates (ADCs)
Immunology
felzartamab Antibody-mediated rejection (AMR) in kidney transplant recipients
Phase 2
—
Antibody-Drug Conjugates (ADCs)
Immunology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A92
Pipeline Score
$66.6B
Pipeline Value
Undervalued
Valuation Signal
114
Drugs Scored
7.8x
rNPV / MCap
Top 99%
Mid Cap
(rank 10 of 905)
Percentile Rank
Biogen Inc. earns an A-grade pipeline score (92/100), with $78.3B risk-adjusted pipeline value, led by Bardoxolone Methyl in Chronic Kidney Disease (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Bardoxolone Methyl
Small molecule		Chronic Kidney DiseasePhase 2NCT0081188943% $8.7B COMPLETED 227 - -Dec 31, 2010 -May 29, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
omaveloxolone
Friedreich ataxia
Phase 3
2025-06-19
omaveloxolone
Friedreich ataxia
Phase 3
2025-06-19
omaveloxolone
Friedreich ataxia
Phase 3
2025-06-19
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in BIIB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BIIB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIIB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIIB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
BIIB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
BIIB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-120 0.00 0 0 - - - - - -
2026-06-120 0.00 0 0 - - - - - -
2026-06-120 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Biogen Inc. (BIIB) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How BIIB ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Systemic Lupus Erythematosus #1 of 32 PHASE 3 Litifilimab
VTRS BMY NVS
$2.78B 0.86 LEADER
Spinal Muscular Atrophy #1 of 7 PHASE 3 Nusinersen
NVS SRRK BHVN
$2.5B 0.89 LEADER
Membranous Nephropathy #1 of 7 PHASE 3 Felzartamab + Tacrolimus
NVS ONC VRTX
$0.39B 0.84 LEADER
Rare Neurological Disorders #2 of 46 PHASE 3 Omaveloxolone
IONS SRPT RARE
$139.4B 0.88 LEADER
ALS #2 of 15 PHASE 3 Tofersen
AMLX IONS NVS
$1.2B 0.91 CONTENDER
Organ Transplant Rejection #2 of 9 PHASE 3 Felzartamab
SNY AZN ARGX
$5.2B 0.84 CONTENDER
Multiple Sclerosis #3 of 20 PHASE 3 BIIB017 + Interferon beta type 1a
SNY NVS BMY
$31.92B 0.94 LEADER
Alzheimer's Disease #3 of 24 PHASE 3 Lecanemab
BMY LLY ANVS
$6.49B 0.88 CONTENDER
IgA Nephropathy #4 of 8 PHASE 3 Felzartamab
NVS VERA TVTX
$46.82B 0.8 CONTENDER
Rare Genetic Disorders #44 of 61 PHASE 3 BIIB111 + BIIB112
BMRN ASND NVS
—0 FOLLOWER